代谢组学在肺癌治疗生物标志物中的研究进展

Advances in metabolomics as the biomarkers for diagnosis and treatment of lung cancer

肺癌具有死亡率高、预后差、5年生存率低的特点,目前以化疗为主的综合治疗方案是非小细胞肺癌(non-small cell lung cancer,NSCLC)的主要治疗方式。根据肺癌的分期分型,患者相应接受包括手术、放疗、化疗以及靶向的综合治疗,然而早期症状不显著、个体化差异巨大、放疗抵抗和化疗耐药等问题限制了患者的诊断和治疗效果,从而严重影响患者的身体健康。代谢组学从小分子代谢物的角度为发掘肿瘤生物标志物、评估整体代谢变化、研究发病机制提供着越来越重要的作用。该文主要综述了基于代谢组学技术的肺癌治疗预后效果评价生物标志物的研究进展,以期为肺癌个体化精准治疗提供重要理论依据,帮助临床患者取得治疗收益的最大化。

Lung cancer is characterized by high mortality,poor prognosis and low 5-year survival rate.At present,the com⁃prehensive treatment based on chemotherapy is the main treatment for non-small cell lung cancer(NSCLC).According to the stage and the type of lung cancer,patients received comprehensive treatment including surgery,radiotherapy,chemotherapy and targeted therapy.However,the not significance of early symptom,the huge difference of individuals,the resistance of radio⁃therapy and chemotherapy limited the diagnosis and treatment,which caused harmful effects to patients.Metabolomics plays an increasingly important role in exploring tumor biomarkers,evaluating overall metabolic changes,and studying pathogenesis.This paper mainly reviewed the research progress of biomarkers for the prognosis effect evaluation of lung cancer treatment based on metabolomics technology,so as to provide an important theoretical basis for the individualized precision treatment of lung cancer and help clinical patients to maximize the treatment benefits.